SBIR/STTR Research Award
PALYTOXIN PRODRUG ACTIVATION BY ANTIBODY-LINKED ENZYME
Award amount
$459,212Program and phase
SBIR · Phase IIAward year
1992Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- HAWAII BIOTECH, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- ECJKEEFL4L51
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
PALYTOXIN IS AN EXTREMELY CYTOTOXIC LOW MOLECULAR WEIGHT NATURAL PRODUCT ISOLATED FROM SOFT CORALS OF THE GENUS, PALYTHOA. N-ACYLATED DERIVATIVES OF PALYTOXIN HAVE BEEN REPORTED TO BE UP TO 100-FOLD LESS CYTOTOXIC THAN THE UNMODIFIED TOXIN. PALYTOXIN N-ACYL DERIVATIVES WHICH CAN BE CONVERTED TO THE NATIVE TOXIN BY ANTITUMOR MONOCLONAL ANTIBODY- ENZYME CONJUGATES WILL BE PREPARED AND TESTED FOR ANTIGEN-SELECTIVE CYTOTOXICITY AGAINST CELLS IN CULTURE.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Chikungunya Recombinant Subunit Vaccine
- Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
- Novel TLR-4 Agonists as Vaccine Adjuvants
- RECOMBINANT WEST NILE VIRUS VACCINE ADJUVANTED WITH SLA-LSQ
- Chikungunya Recombinant Subunit Vaccine
Research funding history
103 SBIR/STTR records share this UEI (1983–2024). Reported award amounts total $40,917,853. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, Department of Agriculture